These results suggest that MFLI FRET imaging can be used to non‐invasively quantify the drug‐target engagement in tumor xenografts as well as characterize the intratumoral spatial distribution of TZM‐HER2 drug‐target engagements across live and intact tumor xenografts. The gene discussed is ERBB2; the disease is neoplasm.